Baxter Faces Escalating Securities Suits Over Novum IQ Pump as Lead-Plaintiff Deadline Nears

Overview

• Bernstein Liebhard said a shareholder filed a class action covering Baxter stock purchases from February 23, 2022 through July 30, 2025, with a lead-plaintiff motion due December 15, 2025.
• Rosen Law Firm and Bronstein, Gewirtz & Grossman are soliciting investors for overlapping class periods, while Bleichmar Fonti & Auld highlighted a case pending in the Northern District of Illinois.
• The complaints allege systemic Novum IQ pump defects causing underinfusion, overinfusion, and non-delivery that exposed patients to severe injury or death.
• Plaintiffs cite Baxter’s April 24 and July 14 customer letters, including disclosure of 79 serious-injury reports and two deaths, followed by the FDA’s Class I recall classification.
• On July 31, Baxter paused Novum IQ shipments and planned installations and said it could not commit to a restart timeline, a disclosure that coincided with a stock drop of more than 22%.